Compliance updated on Jun 19, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Mirum Pharmaceuticals Inc

MIRM ✓ COMPLIANT ☆ Track — members

Nasdaq · Healthcare · Pharmaceuticals ·

USA Mid Cap Analyst: BUY

Last Close

$100.64

▲ +1.89%

Market Cap $6.53B · Vol 142.35K

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$6.53B

Mid Cap

Div Yield

N/A

EPS Growth

-3,222.57%

YoY

RSI (14)

34.87

Momentum

Beta

0.48

vs Market

52W High

$130.00

22.58% below

52W Low

$63.31

58.96% above

Volume

142.35K

Avg 228.35K

P/B

13.03

Price-to-book

ROE

-8.65%

Return on equity

Free Float

86.28%

Public shares

Shariah Compliance8 STANDARDS

✓ Yes, Mirum Pharmaceuticals Inc (MIRM) stock is Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does MIRM pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

-0.01%

-16.75%

-9.65%

-2.39%

YTD

+27.41%

+55.24%

+291.75%

+606.74%

Financials & Valuation

TTM · Annual

Total Revenue	$521.31M
Net Income	$-23,363,000.00
Revenue Growth (YoY)	+37.92%
Gross Margin	80.77%
Operating Margin	-4.25%
Net Profit Margin	-4.48%
ROE	-8.65%
ROA · ROIC	-2.83% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	7.61
P/B	13.03
P/FCF	72.26
EPS Growth	-3,222.57%
Outstanding Shares	64.93M

Technical Indicators

50-Day SMA	$109.99
200-Day SMA	$93.93
RSI (14)	34.87
Beta	0.48
52-Week High	$130.00
52-Week Low	$63.31

Volume Today	142.35K
Avg Daily Volume (30D)	228.35K
Relative Volume	0.62x
Volatility (10D)	69.10
Volatility (30D)	53.42
Free Float	86.28%

Analyst Consensus

BUY

Current Price $100.64

Mean Target $139.77

52W Low$63.31 52W High$130.00

Current

Target

$63.31 $130.00

Current Analyst target

+38.88% upside potential · 14 analysts

Identifiers

ExchangeNasdaq

FIGIBBG00MH7T2N6

ISINUS6047491013

CountryUnited States of America

Sub-IndustryPharmaceuticals (NEC)

Earnings DateOct 29, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

LLY Eli Lilly and Co -2.39% JNJ Johnson & Johnson -0.66% ABBV Abbvie Inc -0.54% NVS Novartis AG -0.55% NOVN.S Novartis AG -1.05%

Company Profile

Mirum Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the treatment of rare diseases affecting children and adults. It has three medicines: LIVMARLI (maralixibat) oral solution (Livmarli), Cholbam (cholic acid) capsules, and Chenodal or Ctexli (chenodiol) tablets. Livmarli is an orally administered, minimally-absorbed ileal bile acid transporter (IBAT) inhibitor (IBATi) that is used for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS) in the United States and various other countries and for cholestatic pruritus in patient with progressive familial intrahepatic cholestasis (PFIC) in the United States, Canada and Japan. Cholbam is used for the treatment of bile acid synthesis disorders due to single enzyme deficiencies and adjunctive treatment of peroxisomal disorders. The Company is also advancing its product candidate, volixibat, for the treatment of adult patients with cholestatic liver diseases.